why choose us

First received: April 06, 2023

Clinical Trial: A Study to Assess Adverse Events and Effectiveness of HAC 22L Injection for Mid-Face Volume in Adult Participants

Study Status: COMPLETED

Recruit Status: COMPLETED

Condition: Facial Volume Deficit

Study Type: INTERVENTIONAL


Official Title: A Multicenter, Evaluator-blinded, Randomized, Delayed Treatment Control Study of the Safety and Effectiveness of HAC 22L for Improving Midface Volume

Brief Summary: Collagen, elastin, and glycosaminoglycans, (eg, hyaluronic acid) are predominant component of the skin and they are key contributor to its characteristics such as strength, elasticity, and plumpness.Chronic reduction in any one of these components as well as a loss of muscle and fat mass contribute to the facial volume loss that characterizes the aging face.HAC 22L is a dermal filler administered via subcutaneous/supraperiosteal injection for volumizing effect.The purpose of the study is to assess adverse…

Read more